Wire · opportunities
Teva's first-in-class Tourette drug filed for approval with FDA priority status
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 August 2026 · Fusion42 review
Teva has filed for FDA approval of ecopipam, a new therapy for pediatric Tourette syndrome, with priority review granted and a target action date in Q1 2027. Ecopipam offers a novel D1 receptor antagonist mechanism and shows improved tolerability compared to current treatments.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 19 Aug 2026 and 20 Aug 2026.
◆ ◆ The Wire takeaway
You can now prepare for competition in pediatric Tourette syndrome therapies as Teva’s novel drug targets a new receptor with fewer side effects. This may open demand for improved treatment options and alternatives to existing D2 blockers.
◆ Coverage
2 sources · first reported 19 Aug 2026 · latest 20 Aug 2026
◆ Related on Wire
◆ Topics